Skip to main content

Table 1 Demographics and baseline disease characteristics

From: A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

  25 mg (n = 1) 50 mg (n = 3) 75 mg (n = 3) 100 mg (n = 10) 125 mg (n = 10) 150 mg (n = 10) 175 mg (n = 3) All patients (n = 40)
Age, years 50 (50–50) 52 (51–64) 53 (48–63) 58 (39–65) 54 (26–63) 55 (39–65) 51 (51–64) 54 (26–65)
Sex
 Female 1 (100) 3 (100) 3 (100) 10 (100) 10 (100) 10 (100) 3 (100) 40 (100)
ECOG performance status
 0 1 (100) 3 (100) 2 (66.7) 4 (40.0) 10 (100) 9 (90.0) 3 (100) 32 (80.0)
 1 0 0 1 (33.3) 6 (60.0) 0 1 (10.0) 0 8 (20.0)
Time since first diagnosis, years 10.9 (10.9–10.9) 5.2 (1.7–11.9) 5.9 (2.4–12.0) 9.6 (4.9–20.3) 6.8 (1.4–20.1) 11.3 (1.0–19.6) 8.2 (8.2–10.5) 8.8 (1.0–20.3)
Tumor stage at study entry
 IV 1 (100) 3 (100) 3 (100) 10 (100) 10 (100) 10 (100) 3 (100) 40 (100)
Previous therapy
 Surgery 1 (100) 3 (100) 3 (100) 10 (100) 10 (100) 10 (100) 3 (100) 40 (100)
 Radiotherapy 1 (100) 3 (100) 3 (100) 8 (80.0) 5 (50.0) 8 (80.0) 3 (100) 31 (77.5)
   Chemotherapy
    1–2 regimens 0 0 2 (66.7) 2 (20.0) 4 (40.0) 3 (30.0) 2 (66.7) 13 (32.5)
    3–6 regimens 1 (100) 0 1 (33.3) 6 (60.0) 4 (40.0) 5 (50.0) 1 (33.3) 18 (45.0)
   Endocrine therapy
    1–2 regimens 0 1 (33.3) 2 (66.7) 4 (40.0) 4 (40.0) 6 (60.0) 3 (100) 20 (50.0)
    3–6 regimens 1 (100) 0 1 (33.3) 3 (30.0) 3 (30.0) 3 (30.0) 0 11 (27.5)
  1. Data are n (%) or median (range)
  2. ECOG Eastern Cooperative Oncology Group